25 XP   0   0   10

Vor Biopharma Inc
Buy, Hold or Sell?

Let's analyse Vor Biopharma Inc together

PenkeI guess you are interested in Vor Biopharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Vor Biopharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Vor Biopharma Inc

I send you an email if I find something interesting about Vor Biopharma Inc.

Quick analysis of Vor Biopharma Inc (30 sec.)










What can you expect buying and holding a share of Vor Biopharma Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.21
Expected worth in 1 year
$0.75
How sure are you?
23.5%

+ What do you gain per year?

Total Gains per Share
$-1.46
Return On Investment
-77.9%

For what price can you sell your share?

Current Price per Share
$1.88
Expected price per share
$1.62 - $2.5
How sure are you?
50%

1. Valuation of Vor Biopharma Inc (5 min.)




Live pricePrice per Share (EOD)

$1.88

Intrinsic Value Per Share

$-16.02 - $-18.72

Total Value Per Share

$-13.81 - $-16.51

2. Growth of Vor Biopharma Inc (5 min.)




Is Vor Biopharma Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$150.7m$194.6m-$4.6m-2.4%

How much money is Vor Biopharma Inc making?

Current yearPrevious yearGrowGrow %
Making money-$28.9m-$22.6m-$6.3m-21.8%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Vor Biopharma Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#302 / 1009

Most Revenue
#815 / 1009

Most Profit
#780 / 1009

Most Efficient
#264 / 1009

What can you expect buying and holding a share of Vor Biopharma Inc? (5 min.)

Welcome investor! Vor Biopharma Inc's management wants to use your money to grow the business. In return you get a share of Vor Biopharma Inc.

What can you expect buying and holding a share of Vor Biopharma Inc?

First you should know what it really means to hold a share of Vor Biopharma Inc. And how you can make/lose money.

Speculation

The Price per Share of Vor Biopharma Inc is $1.88. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Vor Biopharma Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Vor Biopharma Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.21. Based on the TTM, the Book Value Change Per Share is $-0.37 per quarter. Based on the YOY, the Book Value Change Per Share is $0.13 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Vor Biopharma Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.38-20.5%-0.43-23.0%-0.34-18.0%-0.29-15.3%-0.29-15.3%
Usd Book Value Change Per Share-0.35-18.8%-0.37-19.5%0.136.7%0.136.9%0.136.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.35-18.8%-0.37-19.5%0.136.7%0.136.9%0.136.9%
Usd Price Per Share2.25-3.21-5.41-7.27-7.27-
Price to Earnings Ratio-1.46--1.88--4.01--6.78--6.78-
Price-to-Total Gains Ratio-6.38--9.36--12.02--21.37--21.37-
Price to Book Ratio1.02-1.12-1.89-2.14-2.14-
Price-to-Total Gains Ratio-6.38--9.36--12.02--21.37--21.37-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.88
Number of shares531
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.370.13
Usd Total Gains Per Share-0.370.13
Gains per Quarter (531 shares)-194.3869.01
Gains per Year (531 shares)-777.50276.06
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-778-7880276266
20-1555-15660552542
30-2333-23440828818
40-3110-3122011041094
50-3888-3900013801370
60-4665-4678016561646
70-5443-5456019321922
80-6220-6234022082198
90-6998-7012024852474
100-7775-7790027612750

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.017.00.00.0%0.017.00.00.0%0.017.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%4.011.02.023.5%4.011.02.023.5%4.011.02.023.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.017.00.0%0.00.017.00.0%0.00.017.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%4.011.02.023.5%4.011.02.023.5%4.011.02.023.5%

Fundamentals of Vor Biopharma Inc

About Vor Biopharma Inc

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-12 21:43:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Vor Biopharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Vor Biopharma Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Vor Biopharma Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Vor Biopharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--200.1%+200.1%
TTM--216.8%+216.8%
YOY--288.3%+288.3%
5Y--449.1%+449.1%
10Y--605.5%+605.5%
1.1.2. Return on Assets

Shows how efficient Vor Biopharma Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Vor Biopharma Inc to the Biotechnology industry mean.
  • -12.5% Return on Assets means that Vor Biopharma Inc generated $-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Vor Biopharma Inc:

  • The MRQ is -12.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.5%TTM-12.2%-0.3%
TTM-12.2%YOY-9.6%-2.6%
TTM-12.2%5Y-20.5%+8.3%
5Y-20.5%10Y-20.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.5%-13.3%+0.8%
TTM-12.2%-12.8%+0.6%
YOY-9.6%-11.7%+2.1%
5Y-20.5%-13.9%-6.6%
10Y-20.5%-15.7%-4.8%
1.1.3. Return on Equity

Shows how efficient Vor Biopharma Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Vor Biopharma Inc to the Biotechnology industry mean.
  • -17.4% Return on Equity means Vor Biopharma Inc generated $-0.17 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Vor Biopharma Inc:

  • The MRQ is -17.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -15.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.4%TTM-15.6%-1.8%
TTM-15.6%YOY-12.0%-3.7%
TTM-15.6%5Y-26.4%+10.8%
5Y-26.4%10Y-26.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.4%-16.9%-0.5%
TTM-15.6%-16.1%+0.5%
YOY-12.0%-15.1%+3.1%
5Y-26.4%-19.3%-7.1%
10Y-26.4%-20.2%-6.2%

1.2. Operating Efficiency of Vor Biopharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Vor Biopharma Inc is operating .

  • Measures how much profit Vor Biopharma Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Vor Biopharma Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Vor Biopharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM--232.5%+232.5%
YOY--298.2%+298.2%
5Y--492.1%+492.1%
10Y--632.4%+632.4%
1.2.2. Operating Ratio

Measures how efficient Vor Biopharma Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Vor Biopharma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.231-3.231
TTM-3.310-3.310
YOY-3.890-3.890
5Y-5.739-5.739
10Y-7.876-7.876

1.3. Liquidity of Vor Biopharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Vor Biopharma Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 9.04 means the company has $9.04 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Vor Biopharma Inc:

  • The MRQ is 9.042. The company is very able to pay all its short-term debts. +2
  • The TTM is 13.005. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.042TTM13.005-3.963
TTM13.005YOY13.590-0.585
TTM13.0055Y15.786-2.781
5Y15.78610Y15.7860.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.0423.890+5.152
TTM13.0054.173+8.832
YOY13.5905.344+8.246
5Y15.7866.126+9.660
10Y15.7866.448+9.338
1.3.2. Quick Ratio

Measures if Vor Biopharma Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Vor Biopharma Inc to the Biotechnology industry mean.
  • A Quick Ratio of 15.60 means the company can pay off $15.60 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Vor Biopharma Inc:

  • The MRQ is 15.604. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 22.598. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ15.604TTM22.598-6.994
TTM22.598YOY21.075+1.523
TTM22.5985Y18.960+3.639
5Y18.96010Y18.9600.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.6043.514+12.090
TTM22.5983.998+18.600
YOY21.0755.380+15.695
5Y18.9606.105+12.855
10Y18.9606.404+12.556

1.4. Solvency of Vor Biopharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Vor Biopharma Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Vor Biopharma Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.28 means that Vor Biopharma Inc assets are financed with 28.2% credit (debt) and the remaining percentage (100% - 28.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Vor Biopharma Inc:

  • The MRQ is 0.282. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.213. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.282TTM0.213+0.068
TTM0.213YOY0.196+0.017
TTM0.2135Y0.197+0.017
5Y0.19710Y0.1970.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2820.339-0.057
TTM0.2130.336-0.123
YOY0.1960.271-0.075
5Y0.1970.366-0.169
10Y0.1970.389-0.192
1.4.2. Debt to Equity Ratio

Measures if Vor Biopharma Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Vor Biopharma Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 39.2% means that company has $0.39 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Vor Biopharma Inc:

  • The MRQ is 0.392. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.275. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.392TTM0.275+0.117
TTM0.275YOY0.246+0.030
TTM0.2755Y0.256+0.020
5Y0.25610Y0.2560.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3920.388+0.004
TTM0.2750.402-0.127
YOY0.2460.335-0.089
5Y0.2560.426-0.170
10Y0.2560.461-0.205

2. Market Valuation of Vor Biopharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Vor Biopharma Inc generates.

  • Above 15 is considered overpriced but always compare Vor Biopharma Inc to the Biotechnology industry mean.
  • A PE ratio of -1.46 means the investor is paying $-1.46 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Vor Biopharma Inc:

  • The EOD is -1.221. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.461. Based on the earnings, the company is expensive. -2
  • The TTM is -1.884. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.221MRQ-1.461+0.240
MRQ-1.461TTM-1.884+0.423
TTM-1.884YOY-4.010+2.126
TTM-1.8845Y-6.784+4.900
5Y-6.78410Y-6.7840.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.221-2.264+1.043
MRQ-1.461-2.629+1.168
TTM-1.884-2.680+0.796
YOY-4.010-4.145+0.135
5Y-6.784-6.257-0.527
10Y-6.784-6.254-0.530
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Vor Biopharma Inc:

  • The EOD is -1.328. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.590. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.195. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.328MRQ-1.590+0.261
MRQ-1.590TTM-2.195+0.606
TTM-2.195YOY-4.124+1.928
TTM-2.1955Y-6.351+4.155
5Y-6.35110Y-6.3510.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.328-2.973+1.645
MRQ-1.590-3.333+1.743
TTM-2.195-3.553+1.358
YOY-4.124-5.605+1.481
5Y-6.351-8.376+2.025
10Y-6.351-8.865+2.514
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Vor Biopharma Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.02 means the investor is paying $1.02 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Vor Biopharma Inc:

  • The EOD is 0.851. Based on the equity, the company is cheap. +2
  • The MRQ is 1.018. Based on the equity, the company is underpriced. +1
  • The TTM is 1.118. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.851MRQ1.018-0.167
MRQ1.018TTM1.118-0.099
TTM1.118YOY1.894-0.777
TTM1.1185Y2.141-1.023
5Y2.14110Y2.1410.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.8511.896-1.045
MRQ1.0182.115-1.097
TTM1.1182.093-0.975
YOY1.8942.884-0.990
5Y2.1413.542-1.401
10Y2.1413.916-1.775
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Vor Biopharma Inc.

3.1. Institutions holding Vor Biopharma Inc

Institutions are holding 88.435% of the shares of Vor Biopharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31RA Capital Management, LLC33.37140.79952274888000
2023-12-31FMR Inc11.17660.00137618948-32228-0.4212
2023-12-31Paradigm Biocapital Advisors LP9.47250.68026457293-4174-0.0646
2023-12-315AM Venture Management, LLC9.33233.797636172300
2023-09-30LAURION CAPITAL MANAGEMENT LP4.66910.0412318288900
2023-12-31Artal Group S A3.44350.17562347424-340591-12.6707
2023-12-31BlackRock Inc3.30270.000122514111445426.8605
2023-12-31Vanguard Group Inc2.55760.00011743463270171.574
2023-12-31Woodline Partners LP1.630.0272111112300
2023-12-31Johnson & Johnson1.57650.0551107465800
2023-12-31Geode Capital Management, LLC1.16480.0002794063377114.9859
2023-09-30Sarissa Capital Management LP0.90660.176561800000
2023-12-31State Street Corporation0.89190.000160800721000.3466
2023-12-31Northern Trust Corp0.58270.00023972214578013.0264
2023-09-30OUP Management Co., LLC0.54971.786537471400
2023-12-31Mccormack Advisors International0.52390.01063571513571510
2023-12-31Ensign Peak Advisors Inc0.50770.001534608700
2023-12-31Morgan Stanley - Brokerage Accounts0.2524017206195037123.3862
2023-12-31Bridgeway Capital Management, LLC0.23870.007916270000
2023-12-31Bank of New York Mellon Corp0.15870.000110820900
Total 86.30937.560958836025+332345+0.6%

3.2. Funds holding Vor Biopharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Fidelity Growth Compy Commingled Pl O3.09730.0062211135900
2024-02-29Fidelity Growth Company Fund2.14570.0056146270000
2024-02-29Fidelity Select Biotechnology1.63520.0522111470200
2024-02-29Vanguard Total Stock Mkt Idx Inv1.48690.0002101361300
2024-03-28iShares Russell 2000 ETF1.20150.0038190413960.0484
2024-02-29Fidelity VIP Growth Initial0.90720.014361839500
2024-02-29Fidelity Capital Appreciation0.89540.021661040500
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.76230.001251963000
2024-02-29Fidelity Growth Company K60.75480.006451450400
2024-02-29Fidelity Advisor Equity Growth I0.69570.011647426700
2024-03-28iShares Russell 2000 Value ETF0.57240.0074390228-247-0.0633
2024-01-31Fidelity Small Cap Index0.49440.003133705700
2024-02-29Fidelity Series Growth Company0.42590.0042290332-11046-3.6652
2024-02-29Fidelity Growth Discovery0.36130.011246291-604-0.2446
2024-02-29Fidelity Extended Market Index0.30960.0013211029-1022-0.482
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.30350.001120690000
2024-03-31A4Investments SICAV SIF ACCI IlanaA2EURH0.29343.99852000006705650.4393
2023-12-31Bridgeway Ultra-Small Company Market0.2310.190715750000
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.20380.003413890000
2024-02-29Vanguard Russell 2000 ETF0.19840.0033135233106808.5747
Total 16.97574.346311572086+65213+0.6%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Vor Biopharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.353-0.366+4%0.126-380%0.130-371%0.130-371%
Book Value Per Share--2.2102.786-21%2.854-23%2.276-3%2.276-3%
Current Ratio--9.04213.005-30%13.590-33%15.786-43%15.786-43%
Debt To Asset Ratio--0.2820.213+32%0.196+44%0.197+43%0.197+43%
Debt To Equity Ratio--0.3920.275+42%0.246+60%0.256+53%0.256+53%
Dividend Per Share----0%-0%-0%-0%
Eps---0.385-0.432+12%-0.338-12%-0.287-25%-0.287-25%
Free Cash Flow Per Share---0.354-0.371+5%-0.343-3%-0.271-23%-0.271-23%
Free Cash Flow To Equity Per Share---0.353-0.361+2%0.086-510%0.105-438%0.105-438%
Gross Profit Margin--1.0341.008+3%1.000+3%1.002+3%1.002+3%
Intrinsic Value_10Y_max---18.721--------
Intrinsic Value_10Y_min---16.015--------
Intrinsic Value_1Y_max---1.394--------
Intrinsic Value_1Y_min---1.368--------
Intrinsic Value_3Y_max---4.555--------
Intrinsic Value_3Y_min---4.341--------
Intrinsic Value_5Y_max---8.159--------
Intrinsic Value_5Y_min---7.541--------
Market Cap128245704.000-20%153485550.000218972718.000-30%369047478.000-58%495688104.353-69%495688104.353-69%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio0.851-20%1.0181.118-9%1.894-46%2.141-52%2.141-52%
Pe Ratio-1.221+16%-1.461-1.884+29%-4.010+174%-6.784+364%-6.784+364%
Price Per Share1.880-20%2.2503.210-30%5.410-58%7.266-69%7.266-69%
Price To Free Cash Flow Ratio-1.328+16%-1.590-2.195+38%-4.124+159%-6.351+299%-6.351+299%
Price To Total Gains Ratio-5.331+16%-6.380-9.358+47%-12.019+88%-21.368+235%-21.368+235%
Quick Ratio--15.60422.598-31%21.075-26%18.960-18%18.960-18%
Return On Assets---0.125-0.122-2%-0.096-24%-0.205+64%-0.205+64%
Return On Equity---0.174-0.156-10%-0.120-31%-0.264+52%-0.264+52%
Total Gains Per Share---0.353-0.366+4%0.126-380%0.130-371%0.130-371%
Usd Book Value--150724000.000190042500.000-21%194690500.000-23%155284235.294-3%155284235.294-3%
Usd Book Value Change Per Share---0.353-0.366+4%0.126-380%0.130-371%0.130-371%
Usd Book Value Per Share--2.2102.786-21%2.854-23%2.276-3%2.276-3%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.385-0.432+12%-0.338-12%-0.287-25%-0.287-25%
Usd Free Cash Flow---24137000.000-25340250.000+5%-23401500.000-3%-18480000.000-23%-18480000.000-23%
Usd Free Cash Flow Per Share---0.354-0.371+5%-0.343-3%-0.271-23%-0.271-23%
Usd Free Cash Flow To Equity Per Share---0.353-0.361+2%0.086-510%0.105-438%0.105-438%
Usd Market Cap128245704.000-20%153485550.000218972718.000-30%369047478.000-58%495688104.353-69%495688104.353-69%
Usd Price Per Share1.880-20%2.2503.210-30%5.410-58%7.266-69%7.266-69%
Usd Profit---26261000.000-28968500.000+10%-22643500.000-14%-18975117.647-28%-18975117.647-28%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.353-0.366+4%0.126-380%0.130-371%0.130-371%
 EOD+3 -5MRQTTM+16 -14YOY+4 -265Y+6 -2410Y+6 -24

4.2. Fundamental Score

Let's check the fundamental score of Vor Biopharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.221
Price to Book Ratio (EOD)Between0-10.851
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than115.604
Current Ratio (MRQ)Greater than19.042
Debt to Asset Ratio (MRQ)Less than10.282
Debt to Equity Ratio (MRQ)Less than10.392
Return on Equity (MRQ)Greater than0.15-0.174
Return on Assets (MRQ)Greater than0.05-0.125
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Vor Biopharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.441
Ma 20Greater thanMa 501.995
Ma 50Greater thanMa 1002.033
Ma 100Greater thanMa 2002.157
OpenGreater thanClose1.850
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets209,828
Total Liabilities59,104
Total Stockholder Equity150,724
 As reported
Total Liabilities 59,104
Total Stockholder Equity+ 150,724
Total Assets = 209,828

Assets

Total Assets209,828
Total Current Assets140,803
Long-term Assets69,025
Total Current Assets
Cash And Cash Equivalents 31,360
Short-term Investments 105,815
Other Current Assets 3,628
Total Current Assets  (as reported)140,803
Total Current Assets  (calculated)140,803
+/-0
Long-term Assets
Property Plant Equipment 50,098
Long-term Assets Other 4,812
Long-term Assets  (as reported)69,025
Long-term Assets  (calculated)54,910
+/- 14,115

Liabilities & Shareholders' Equity

Total Current Liabilities15,572
Long-term Liabilities43,532
Total Stockholder Equity150,724
Total Current Liabilities
Short-term Debt 3,830
Accounts payable 815
Other Current Liabilities 10,927
Total Current Liabilities  (as reported)15,572
Total Current Liabilities  (calculated)15,572
+/-0
Long-term Liabilities
Capital Lease Obligations 35,660
Long-term Liabilities  (as reported)43,532
Long-term Liabilities  (calculated)35,660
+/- 7,872
Total Stockholder Equity
Common Stock7
Retained Earnings -340,080
Accumulated Other Comprehensive Income -77
Other Stockholders Equity 490,874
Total Stockholder Equity (as reported)150,724
Total Stockholder Equity (calculated)150,724
+/-0
Other
Capital Stock7
Cash and Short Term Investments 137,175
Common Stock Shares Outstanding 67,891
Liabilities and Stockholders Equity 209,828
Net Debt 4,300
Net Invested Capital 150,724
Net Working Capital 125,231
Property Plant and Equipment Gross 58,189
Short Long Term Debt Total 35,660



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
> Total Assets 
9,826
0
0
88,525
75,908
292,939
275,143
258,632
242,590
234,269
224,615
206,373
299,366
277,533
250,986
223,023
209,828
209,828223,023250,986277,533299,366206,373224,615234,269242,590258,632275,143292,93975,90888,525009,826
   > Total Current Assets 
7,539
74,813
74,813
65,524
49,106
266,265
249,265
232,072
214,399
190,303
158,843
142,729
236,950
216,898
191,393
164,438
140,803
140,803164,438191,393216,898236,950142,729158,843190,303214,399232,072249,265266,26549,10665,52474,81374,8137,539
       Cash And Cash Equivalents 
6,466
0
0
63,604
48,539
262,567
169,516
143,034
119,801
90,042
62,952
60,827
57,706
42,455
32,212
45,026
31,360
31,36045,02632,21242,45557,70660,82762,95290,042119,801143,034169,516262,56748,53963,604006,466
       Short-term Investments 
0
0
0
0
0
0
75,118
82,934
87,668
91,575
88,136
75,240
172,539
167,745
154,690
115,072
105,815
105,815115,072154,690167,745172,53975,24088,13691,57587,66882,93475,118000000
       Other Current Assets 
205
851
851
219
100
92
65
749
2,094
2,212
2,288
1,771
2,337
459
539
667
3,628
3,6286675394592,3371,7712,2882,2122,0947496592100219851851205
   > Long-term Assets 
2,287
0
0
23,001
26,802
26,674
25,878
26,560
28,191
43,966
65,772
63,644
62,416
60,635
59,593
58,585
69,025
69,02558,58559,59360,63562,41663,64465,77243,96628,19126,56025,87826,67426,80223,001002,287
       Property Plant Equipment 
728
19,814
19,814
21,087
21,845
22,533
22,208
22,006
22,523
33,364
60,974
58,353
57,078
55,431
53,912
52,086
50,098
50,09852,08653,91255,43157,07858,35360,97433,36422,52322,00622,20822,53321,84521,08719,81419,814728
       Long-term Assets Other 
1,559
0
0
1,914
4,957
4,141
3,670
4,554
-82,000
10,602
2,385
2,878
2,925
2,791
3,268
4,086
4,812
4,8124,0863,2682,7912,9252,8782,38510,602-82,0004,5543,6704,1414,9571,914001,559
> Total Liabilities 
2,186
0
0
25,331
27,637
25,752
25,035
25,675
26,327
39,822
49,641
47,639
48,759
47,318
46,536
48,242
59,104
59,10448,24246,53647,31848,75947,63949,64139,82226,32725,67525,03525,75227,63725,331002,186
   > Total Current Liabilities 
2,186
3,946
3,946
7,600
10,207
8,631
8,304
9,210
10,153
18,145
12,262
11,102
13,119
12,579
12,717
15,388
15,572
15,57215,38812,71712,57913,11911,10212,26218,14510,1539,2108,3048,63110,2077,6003,9463,9462,186
       Short-term Debt 
0
0
0
713
863
1,155
1,164
1,147
1,839
7,281
4,429
3,757
3,272
3,713
3,691
3,743
3,830
3,8303,7433,6913,7133,2723,7574,4297,2811,8391,1471,1641,155863713000
       Accounts payable 
693
1,659
1,659
2,321
2,361
2,406
2,369
1,957
1,545
1,255
1,268
824
1,772
3,216
1,648
1,309
815
8151,3091,6483,2161,7728241,2681,2551,5451,9572,3692,4062,3612,3211,6591,659693
       Other Current Liabilities 
1,493
563
563
412
723
675
478
430
434
9,609
6,565
6,521
8,075
5,650
268
419
10,927
10,9274192685,6508,0756,5216,5659,6094344304786757234125635631,493
   > Long-term Liabilities 
25,069
0
0
17,731
17,430
17,121
16,731
16,465
16,174
21,677
37,379
36,537
35,640
34,739
33,819
32,854
43,532
43,53232,85433,81934,73935,64036,53737,37921,67716,17416,46516,73117,12117,43017,7310025,069
> Total Stockholder Equity
7,640
0
0
63,194
48,271
267,187
250,108
232,957
216,263
194,447
174,974
158,734
250,607
230,215
204,450
174,781
150,724
150,724174,781204,450230,215250,607158,734174,974194,447216,263232,957250,108267,18748,27163,194007,640
   Common Stock
0
0
0
0
1
4
4
4
4
4
4
4
7
7
7
7
7
77777444444410000
   Retained Earnings Total Equity000-250,650-222,217-198,307-174,519-152,860-130,123-111,871-93,317-74,94700000
   Accumulated Other Comprehensive Income -77-280-436-174-770-1,178-1,326-1,0720-258,632-275,143-292,9390000-121
   Capital Surplus 
0
0
0
0
0
342,130
343,421
344,824
346,382
348,375
350,815
358,215
473,587
481,032
0
0
0
000481,032473,587358,215350,815348,375346,382344,824343,421342,13000000
   Treasury Stock00000000000000000
   Other Stockholders Equity 
458
0
0
1,419
2,158
342,130
343,421
344,824
346,382
348,375
350,815
358,215
473,587
481,032
485,508
488,873
490,874
490,874488,873485,508481,032473,587358,215350,815348,375346,382344,824343,421342,1302,1581,41900458



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-3,492
Gross Profit-3,492-3,492
 
Operating Income (+$)
Gross Profit-3,492
Operating Expense-122,544
Operating Income-126,036-126,036
 
Operating Expense (+$)
Research Development94,315
Selling General Administrative31,721
Selling And Marketing Expenses3,492
Operating Expense122,544129,528
 
Net Interest Income (+$)
Interest Income7,125
Interest Expense-0
Other Finance Cost-0
Net Interest Income7,125
 
Pretax Income (+$)
Operating Income-126,036
Net Interest Income7,125
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-117,863-134,209
EBIT - interestExpense = -126,036
-117,863
-117,863
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-126,036-117,863
Earnings Before Interest and Taxes (EBITDA)-122,544
 
After tax Income (+$)
Income Before Tax-117,863
Tax Provision-0
Net Income From Continuing Ops-115,512-117,863
Net Income-117,863
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses126,036
Total Other Income/Expenses Net8,173-7,125
 

Technical Analysis of Vor Biopharma Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Vor Biopharma Inc. The general trend of Vor Biopharma Inc is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Vor Biopharma Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Vor Biopharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.43 < 2.43 < 2.5.

The bearish price targets are: 1.62 > 1.62.

Tweet this
Vor Biopharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Vor Biopharma Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Vor Biopharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Vor Biopharma Inc. The current macd is -0.08593628.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Vor Biopharma Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Vor Biopharma Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Vor Biopharma Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Vor Biopharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartVor Biopharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Vor Biopharma Inc. The current adx is 16.01.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Vor Biopharma Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Vor Biopharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Vor Biopharma Inc. The current sar is 2.0356988.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Vor Biopharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Vor Biopharma Inc. The current rsi is 46.44. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Vor Biopharma Inc Daily Relative Strength Index (RSI) ChartVor Biopharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Vor Biopharma Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Vor Biopharma Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Vor Biopharma Inc Daily Stochastic Oscillator ChartVor Biopharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Vor Biopharma Inc. The current cci is -47.67026674.

Vor Biopharma Inc Daily Commodity Channel Index (CCI) ChartVor Biopharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Vor Biopharma Inc. The current cmo is -3.25485521.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Vor Biopharma Inc Daily Chande Momentum Oscillator (CMO) ChartVor Biopharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Vor Biopharma Inc. The current willr is -61.40350877.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Vor Biopharma Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Vor Biopharma Inc Daily Williams %R ChartVor Biopharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Vor Biopharma Inc.

Vor Biopharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Vor Biopharma Inc. The current atr is 0.15031775.

Vor Biopharma Inc Daily Average True Range (ATR) ChartVor Biopharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Vor Biopharma Inc. The current obv is -2,538,146.

Vor Biopharma Inc Daily On-Balance Volume (OBV) ChartVor Biopharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Vor Biopharma Inc. The current mfi is 53.05.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Vor Biopharma Inc Daily Money Flow Index (MFI) ChartVor Biopharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Vor Biopharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Vor Biopharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Vor Biopharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.441
Ma 20Greater thanMa 501.995
Ma 50Greater thanMa 1002.033
Ma 100Greater thanMa 2002.157
OpenGreater thanClose1.850
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Vor Biopharma Inc with someone you think should read this too:
  • Are you bullish or bearish on Vor Biopharma Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Vor Biopharma Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Vor Biopharma Inc

I send you an email if I find something interesting about Vor Biopharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Vor Biopharma Inc.

Receive notifications about Vor Biopharma Inc in your mailbox!